



# Becoming The Gateway to European Extracts

---

June 2020

# Overview

## COMPANY OVERVIEW

- EXMceuticals Inc. (EXM) is a publicly traded cannabis company (CSE: EXM) pioneering the European marketplace through EU GMP certified extraction capabilities and production of unique cannabinoid formulations
- EXM operates through a wholly owned license import / extraction license in Portugal, which is the gateway into EU cannabis market
  - Existing fully equipped R&D facility and approved pilot refinery
  - Developing state of the art, full scale extraction facility with 20,000kg/year refining capacity
- Portugal facility provides access to the largely untapped European cannabis market and “hub and spoke” model to produce a variety of highly purified cannabinoids that can be utilized in pharmaceutical and nutraceutical formulations
- Management and operations team has proven experience in licensing, import, R&D, extraction, purification and formulation
- Current capitalization and tight float provides well structured public company vehicle

## R&D FACILITY



*EXM is uniquely positioned in the European market with a clear path to an EU GMP licensed facility as well as a dedicated focus on large scale refining and distribution*

# Focus on Extraction and Refining for the European Market

*EXM is focused on creating EU GMP certified cannabinoids with high quality standards that can be utilized across a wide variety of formulations for the medical and consumer goods markets*



EXM is building out its large-scale refinery, with proven extraction and refining capabilities, to distribute to the untapped EU cannabinoid market

# Why EXM Today?

*Licenses and positioning in the EU create the optimal environment for EXM to thrive*

Approved license  
in Portugal

- Unique license obtained for cannabis importation, research and development from INFARMED
- Operational pilot cannabinoids and terpenes refinery
- Multiple existing R&D partnerships

Fully planned  
facility and  
support staff


- 1500sq meter building secured facility preapproved by the Portuguese Authority
- Staff of qualified specialists in large scale extraction and refining

Fully planned  
facility and  
support staff

- Multiple supply agreement in place for CBD and THC with global cannabis companies
- Offtake agreements with leading European medical and wellness companies

# \$120b+ European Market with Limited Competition

- Europe is set to become the world's largest legal cannabis market over the next five years
- In the last 12 months alone, the European cannabis industry has grown more than in the last six years
- Six countries have announced new legislation and over €500million has been invested in European cannabis businesses



EXM is pioneering the large and underserved European cannabis market

# Highlights

1 Pure-Play European cannabis extraction, refining and purification opportunity

2 Existing R&D lab and pilot facility with plan for cost efficient EU-GMP expansion

3 Focused on becoming a dominant beachhead for the industry to access Europe

4 A team that has created over 5 billion in shareholder value

# Assets Overview

---



## R&D Facility

Fully equipped, operational and staffed

R&D facility and pilot R&D refinery inspected and approved by INFARMED Nov 2019

Portugal 2020 Research projects underway

Application for COVID-19 research


## Refinery Facility

Fitting and licensing underway to be completed in early 2021

State-of-the-art facility will operate to the highest standards and regulations of the Portuguese Government and EU, allowing EXM to export for the RoW

Refinery will be one of world's most technologically advanced facilities for pharmaceutical cannabinoid production, according to EU-GMP guidelines. Quality, consistency, and standardization assured.

# Milestones





# Management

## Jonathan Summers – CEO

- Former Managing Director at Goldman Sachs in London, having spent 15 years at the Firm (1996-2011)
- Founding partner and the Head of Business Development for Everett Capital Advisors, a \$600mn (USD) London based Investment fund
- Founding Principal and Head of Business Development, for Myriad Asset Management; a \$5bn (USD) Hong Kong-based multi-strategy asset management firm

## Tanek Amin – Head Corporate Development

- Mr. Amin is a senior finance and operations professional with over 15 years of international work experience spanning investment banking, international development, emerging markets private equity, business development and start-up operations.
- Mr. Amin has spent most of his career as a mergers and acquisitions investment banker at Merrill Lynch & Co. and Jefferies International, where he executed over \$20bn in M&A transactions and associated equity and debt financings for various companies across a wide range of industries including Healthcare and Food & Beverage. Mr. Amin has advised various life science and healthcare companies and also spent time working in the business development group at Pfizer.

## Paulo Martins – CEO-Portugal Operations

- Mr. Martins has over 20 years of experience working in management, project development and project implementation, besides law and compliance affairs. He is a corporate and business lawyer specialized in project management, corporate finance, mergers & acquisitions, licensing and companies general management

## Julie Lemieux – VP North American Operations

- Mrs. Lemieux has over 20 years of experience in business, assisting large and small corporations across Canada to attain new levels of success and implement sustainable organizational changes. She has facilitated the reorganization of operational processes to improve efficiency and align strategic priorities for major oil and gas companies, environmental and engineering firms, governments, indigenous groups and national organizations

# Management (cont.)

## Michael Kinley – CFO

- Mr. Kinley, a former partner with KPMG, has been the President of Winslow Associates Management & Communications Inc. since 1993, a private consulting firm which provides professional services to junior public companies. Mr. Kinley is a Chartered Professional Accountant and has served as an officer and director for several public companies over the past thirty years

## Susana Santos – Director Science and Genetics

- Mrs. Santos majored in Genetics and Microbiology at Lisbon's Faculty of Sciences. Susana holds a PhD in Molecular Biology (Lisbon's Faculty of Sciences) as well as a Post-Doc in Molecular Biology (Lisbon's Faculty of Pharmacy). In 2013, she became a co-founder of the start-up HeartGenetics, Genetics and Biotechnology a company that pioneers a methodology that integrates Genomics and Computational Technologies

## Adilia Charmier – VP Research and Development

- Mrs. Charmier obtained a Ph.D. in Organic Chemistry and a Master of Science in Chemistry from the Université Blaise Pascal in France. Mrs. Charmier has published over 25 scientific papers, has been a speaker at 35 scientific conferences, and she holds 3 patents

# Contact Us



Jonathan Summers - CEO and Chairman  
[jonathan@exmceuticals.com](mailto:jonathan@exmceuticals.com)



In Portugal: Paulo Martins -  
[pmartins@exmceuticals.com](mailto:pmartins@exmceuticals.com)



[investors@exmceuticals.com](mailto:investors@exmceuticals.com)



[www.exmceuticals.com](http://www.exmceuticals.com)

# Disclaimer

---

June 2020 This presentation was prepared by management of EXMceuticals Inc. (“EXM”). The information contained in this presentation ( is provided as at the date hereof and is subject to change without notice, notice,( does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in EXM, and ( is not to be considered as a recommendation by EXM that any person make an investment. Any investment in the securities of EXM is speculative and involves a number of risks that should be considered by any prospective investor. Additional information regarding EXM, including the risks and uncertainties outlined in its most recent annual information form dated October XX 2019 (the “Annual Information Form”) and short form prospectus dated June 10 2019 (the “ is available at [www.exmceuticals.com](http://www.exmceuticals.com) or through the SEDAR website at [www.sedar.com](http://www.sedar.com). This presentation does not constitute an offer or solicitation in any jurisdiction to any person or entity and was not prepared in connection with any such offer or solicitation. Readers of this presentation should not construe the contents of this presentation as legal, investment, tax or other advice.

EXMceuticals cautions that statements in this presentation (including any oral commentary that may accompany it) are forward looking statements All statements, other than statements of historical facts, contained in this presentation, including statements regarding our future results of operations or financial condition, prospects, business strategy and plans and objectives of management for future operations, the success of our sales and marketing efforts, the extent of market acceptance for our products and services, our ability to develop and bring to market new or enhanced products, our ability to develop our production facility, our international ventures, the cannabis and cannabis industry and regulatory environment and continuing uncertainty in the global economic environment, are forward looking statements The words “ believe,” “ may,” “ estimate,” “ continue,” “ projection”, “ anticipate,” “ intend,” “ should,” “ plan,” “ expect,” “ predict,” “ could,” “ or other similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words Actual results and trends in the future may differ materially from those suggested or implied by the forward looking statements depending on a variety of factors. The forward looking statements contained in this presentation speak only as of the date the statements are made and are based on information available to the EXM at the time those statements are made and/or management’s good faith belief as of that time with respect to future events Such statements are based upon the current beliefs and expectations of EXM’ management and are subject to significant business, social, economic, political, regulatory, competitive and other risks, uncertainties, contingencies and other factors. Many assumptions are based on factors and events that are not within the control of EXM. Actual future results may differ materially from historical results or current expectations. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward looking information contained in this presentation, those results or developments may not be indicative of results or developments in subsequent periods Although EXM has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended Forward looking information contained in this presentation is based on EXM’ current estimates, expectations and projections, which EXM believes are reasonable as of the current date EXM can give no assurance that these estimates, expectations and projections will prove to have been correct. You should not place undue reliance on forward looking information, which is based on the information available as of the date of this presentation Forward looking information contained in this presentation is as of the date of this presentation and, except as required by applicable law, the Company assumes no obligation to update or revise them to reflect new events or circumstances Historical statements should not be taken as a representation that such trends will be replicated in the future No statement in this presentation is intended to be nor may be construed as a profit forecast Additional information related to EXM, including risks and uncertainties and the Annual Information Form and Prospectus, can be found on its SEDAR profile at [www.Sedar.com](http://www.Sedar.com) All analyst coverage is conducted by third parties Please note that any opinions, estimates or forecasts regarding EXM’ performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of EXM or its management. As such the content of any analyst coverage should not be considered financial advice or forecasting that is approved or endorsed by EXM